A prospective, multi-centre, randomized, double blind, parallel, active controlled, phase III study to compare the efficacy, safety, and immunogenicity of Aflibercept of Shilpa Biologicals Private Limited (SBPL) with EYLEA® (Aflibercept) of Bayer AG in subjects with Neovascular Age-related Macular Degeneration (Wet AMD) - NIL
/ Not yet recruitingNot Applicable A Prospective Assessment of Antibiotic Induced Adverse Drug Reaction In Orthopaedic Department - NIL
A Prospective, Randomized, Double Blind, Multidose, Multicenter, Parallel Group, Active Controlled Phase III Study to Compare Clinical Efficacy and Safety of Shilpa Adalimumab with Humira�® (Adalimumab) in Patients with Active Rheumatoid Arthritis. - NA
100 Clinical Results associated with Shilpa Biologicals Pvt Ltd.
0 Patents (Medical) associated with Shilpa Biologicals Pvt Ltd.
100 Deals associated with Shilpa Biologicals Pvt Ltd.
100 Translational Medicine associated with Shilpa Biologicals Pvt Ltd.